XTANDI: the first and only androgen receptor inhibitor-based regimen to demonstrate overall survival benefit in non-metastatic hormone-sensitive prostate cancer (nmHSPC) with high-risk biochemical ...
Pfizer Inc. (NYSE: PFE) today announced positive topline results from the Phase 3 TALAPRO-3 study of TALZENNA ® (talazoparib), an oral poly ADP-ribose polymerase (PARP) inhibitor, in combination with ...
Hosted on MSN
Expert Q&A: The Link Between Fatigue and Advanced Prostate Cancer — Plus Tips to Manage It
Many people with prostate cancer experience fatigue as a symptom of the cancer and as a side effect of treatment. In fact, up to 90 percent of men with prostate cancer experience fatigue.
A global phase 3 trial enrolled mHSPC with ≥90% PTEN loss by IHC and randomized 1,012 patients to intermittent capivasertib plus abiraterone/prednisone versus ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results